From bench to bedside: evolving therapeutic targets in autoimmune blistering disease

K. Kridin, E. H. Kowalski, D. Kneiber, R. Laufer-Britva, K. T. Amber

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


Autoimmune blistering diseases comprise a group of heterogenous conditions characterized by the loss of tolerance and subsequent development of autoantibodies targeting epidermal and subepidermal adhesion proteins. Blisters and erosions form on the skin and mucous membranes leading to significant morbidity and mortality. Traditional therapies rely on systemic immunosuppression. Advancements in our understanding of the pathophysiology of pemphigus and pemphigoid have led to the development of molecules which target specific pathways involved in induction and perpetuation of disease. In this review, we outline the novel therapeutic strategies including B-cell depletion, T-regulatory cell repletion, cell signalling inhibitors and small molecular inhibitors, inhibitory monoclonal antibodies, as well as complement inhibition. We additionally review their current level of clinical evidence. We lastly review therapeutics targets gleaned from the experimental epidermolysis bullosa acquisita mouse model. These emerging treatments offer an exciting progression from basic science discoveries that have the potential to transform the treatment paradigm in autoimmune blistering diseases.

Original languageEnglish
Pages (from-to)2239-2252
Number of pages14
JournalJournal of the European Academy of Dermatology and Venereology
Issue number12
StatePublished - 1 Dec 2019
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2019 European Academy of Dermatology and Venereology


Dive into the research topics of 'From bench to bedside: evolving therapeutic targets in autoimmune blistering disease'. Together they form a unique fingerprint.

Cite this